SG11202009938TA - Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators - Google Patents
Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulatorsInfo
- Publication number
- SG11202009938TA SG11202009938TA SG11202009938TA SG11202009938TA SG11202009938TA SG 11202009938T A SG11202009938T A SG 11202009938TA SG 11202009938T A SG11202009938T A SG 11202009938TA SG 11202009938T A SG11202009938T A SG 11202009938TA SG 11202009938T A SG11202009938T A SG 11202009938TA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazo
- dopamine
- receptor positive
- positive modulators
- tetrahydroisoquinoline derivatives
- Prior art date
Links
- 102000004076 Dopamine D1 Receptors Human genes 0.000 title 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660622P | 2018-04-20 | 2018-04-20 | |
| PCT/US2019/027842 WO2019204418A1 (en) | 2018-04-20 | 2019-04-17 | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009938TA true SG11202009938TA (en) | 2020-11-27 |
Family
ID=66324031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009938TA SG11202009938TA (en) | 2018-04-20 | 2019-04-17 | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10611751B2 (en) |
| EP (1) | EP3781560B1 (en) |
| JP (1) | JP7083916B2 (en) |
| KR (1) | KR102520872B1 (en) |
| CN (1) | CN111971282B (en) |
| AR (1) | AR114467A1 (en) |
| AU (1) | AU2019256350B2 (en) |
| BR (1) | BR112020019934A2 (en) |
| CA (1) | CA3097692C (en) |
| CL (1) | CL2020002697A1 (en) |
| CO (1) | CO2020012678A2 (en) |
| CR (1) | CR20200481A (en) |
| EA (1) | EA202092146A1 (en) |
| EC (1) | ECSP20066271A (en) |
| ES (1) | ES2927142T3 (en) |
| IL (1) | IL278045B2 (en) |
| JO (1) | JOP20200263A1 (en) |
| MA (1) | MA52286A (en) |
| MX (1) | MX2020010914A (en) |
| MY (1) | MY197645A (en) |
| NZ (1) | NZ767900A (en) |
| PE (1) | PE20201151A1 (en) |
| PH (1) | PH12020551713A1 (en) |
| SA (1) | SA520420382B1 (en) |
| SG (1) | SG11202009938TA (en) |
| TW (1) | TWI725408B (en) |
| UA (1) | UA125271C2 (en) |
| WO (1) | WO2019204418A1 (en) |
| ZA (1) | ZA202006439B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220251064A1 (en) * | 2019-07-01 | 2022-08-11 | UCB Biopharma SRL | A Substituted Tetrahydroisoquinoline Derivative as a D1 Positive Allosteric Modulator |
| CN117700395A (en) | 2019-07-01 | 2024-03-15 | Ucb生物制药有限责任公司 | Substituted tetrahydroisoquinoline derivatives as D1 positive allosteric modulators |
| CN116615198A (en) | 2020-12-18 | 2023-08-18 | Ucb生物制药有限责任公司 | Dihydroisoquinolinyl derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330360B1 (en) | 1988-02-19 | 1993-12-01 | SmithKline Beecham Farmaceutici S.p.A. | 1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| CN1244561C (en) | 2000-05-11 | 2006-03-08 | 布里斯托尔-迈尔斯斯奎布公司 | Tetrahydroixoquinoline analogs useful as growth hormone secretagogues |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| AR095883A1 (en) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | HETEROCYCLIC ACETAMIDE COMPOUNDS |
| JO3316B1 (en) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | 3,4-dihydroisoquinolin-2(1h)-yl compounds |
| WO2016055482A1 (en) | 2014-10-08 | 2016-04-14 | Ucb Biopharma Sprl | Isoindoline derivatives |
| CN107001278B (en) * | 2014-10-08 | 2020-11-24 | Ucb生物制药私人有限公司 | Tetrahydroisoquinoline derivatives |
| AR105025A1 (en) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | IMIDAZODIAZEPIN COMPOUND |
| AR106332A1 (en) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | CRYSTALLINE FORM OF 2- (2,6-DICLOROPHENIL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTYL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETANONA |
| US10370355B2 (en) | 2016-04-13 | 2019-08-06 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| US20210040074A1 (en) | 2018-03-06 | 2021-02-11 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
-
2019
- 2019-04-03 TW TW108111844A patent/TWI725408B/en active
- 2019-04-04 AR ARP190100882A patent/AR114467A1/en unknown
- 2019-04-17 CN CN201980027079.8A patent/CN111971282B/en active Active
- 2019-04-17 CA CA3097692A patent/CA3097692C/en active Active
- 2019-04-17 JP JP2020557950A patent/JP7083916B2/en active Active
- 2019-04-17 MY MYPI2020005419A patent/MY197645A/en unknown
- 2019-04-17 IL IL278045A patent/IL278045B2/en unknown
- 2019-04-17 MA MA052286A patent/MA52286A/en unknown
- 2019-04-17 US US16/386,684 patent/US10611751B2/en active Active
- 2019-04-17 UA UAA202005900A patent/UA125271C2/en unknown
- 2019-04-17 SG SG11202009938TA patent/SG11202009938TA/en unknown
- 2019-04-17 KR KR1020207029608A patent/KR102520872B1/en active IP Right Grant
- 2019-04-17 CR CR20200481A patent/CR20200481A/en unknown
- 2019-04-17 MX MX2020010914A patent/MX2020010914A/en unknown
- 2019-04-17 AU AU2019256350A patent/AU2019256350B2/en active Active
- 2019-04-17 EP EP19720352.4A patent/EP3781560B1/en active Active
- 2019-04-17 BR BR112020019934-6A patent/BR112020019934A2/en unknown
- 2019-04-17 JO JOP/2020/0263A patent/JOP20200263A1/en unknown
- 2019-04-17 PE PE2020001478A patent/PE20201151A1/en unknown
- 2019-04-17 ES ES19720352T patent/ES2927142T3/en active Active
- 2019-04-17 EA EA202092146A patent/EA202092146A1/en unknown
- 2019-04-17 WO PCT/US2019/027842 patent/WO2019204418A1/en active Application Filing
- 2019-04-17 NZ NZ767900A patent/NZ767900A/en unknown
-
2020
- 2020-10-09 PH PH12020551713A patent/PH12020551713A1/en unknown
- 2020-10-13 CO CONC2020/0012678A patent/CO2020012678A2/en unknown
- 2020-10-16 CL CL2020002697A patent/CL2020002697A1/en unknown
- 2020-10-16 ZA ZA2020/06439A patent/ZA202006439B/en unknown
- 2020-10-19 SA SA520420382A patent/SA520420382B1/en unknown
- 2020-10-19 EC ECSENADI202066271A patent/ECSP20066271A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259424B (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| PT3625222T (en) | Phenyl derivatives as pge2 receptor modulators | |
| HRP20190024T1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| IL278045A (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| IL268263B (en) | Estrogen receptor modulators | |
| HK1247914A1 (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| ZA202102487B (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators |